William J Febbo bought $100k of OPRX
CEO at OptimizeRx Corp. 20,000 shares at an average of $5.01, traded Dec 12, 2024, filed Dec 16, 2024.
Score components
- +25RoleCEO
- +10Trade size$100k at market
- 0Relative to holdingsHoldings up 3.4%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.1%, 3m +55.5%, 6m +158.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-051352, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2024 | POpen-market purchase Common Stock | +20,000 | $5.01 | $100k | 601,253 | Dec 16, 2024 |
Related signals
Other insiders at OptimizeRx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | OPRXsell OptimizeRx Corp | Edward Stelmakh Chief Finance & Strat Officer | $19k 1,388 shares | -1% | |
| 15Weak | OPRXsell OptimizeRx Corp | Stephen L Silvestro Chief Executive Officer | $30k 1,620 shares | -1% | |
| 32Weak | OPRXsell OptimizeRx Corp | Patrick D Spangler director | $194k 11,120 shares | -20% | |
| 12Weak | OptimizeRx Corp | Marion Odence-Ford General Counsel and CCO | $61k 4,000 shares | -26% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.